Skip to main content

NeoGenomics Moves to Nasdaq Capital Market

NEW YORK (GenomeWeb News) – NeoGenomics has been approved to list its shares on the Nasdaq Capital Market, the Ft. Myers, Fla.-based firm said today.

The company's stock is currently traded on the OTC Bulletin Board under ticker symbol "NGNM." Starting Dec. 10, NeoGenomics will list on Nasdaq under ticker symbol "NEO."

"The transition to the Nasdaq Capital Market is a significant milestone for NeoGenomics and reflects the strong revenue and operating income growth we have achieved over the last several years," NeoGenomics Chairman and CEO Douglas VanOort said in a statement. "We believe this move will increase the visibility and liquidity of our shares in the market."

In late October NeoGenomics reported that its revenues in the third quarter improved 26 percent year over year.

In late afternoon trading today, shares of the company rose 4 percent to $2.81

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.